Clinical Trial Update: A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study evaluating pembrolizumab plus enfortumab vedotin, with or without investigational agents, as first-line t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma
• Urothelial Neoplasms

Drugs mentioned

• Enfortumab Vedotin (Padcev) (enfortumab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Urothelial Carcinoma, Urothelial Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING